### Papua New Guinea

**Population 2017**: 8.3 million

#### Tuberculosis profile

**Estimates of TB burden**, 2017

<table>
<thead>
<tr>
<th></th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>4.3 (2.9–6)</td>
<td>53 (36–73)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>0.92 (0.51–1.5)</td>
<td>11 (6.1–18)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>36 (29–43)</td>
<td>432 (352–521)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>3.5 (2–5.4)</td>
<td>42 (24–66)</td>
</tr>
<tr>
<td>Incidence (MDR/RR-TB)**</td>
<td>1.9 (1.2–2.8)</td>
<td>23 (15–34)</td>
</tr>
</tbody>
</table>

**Estimated TB incidence by age and sex (thousands)**, 2017

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Total</th>
<th>Females</th>
<th>Males</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-14 years</td>
<td>13 (9.3–16)</td>
<td>1.8 (1.3–2.4)</td>
<td>2 (1.4–2.6)</td>
</tr>
<tr>
<td>&gt; 14 years</td>
<td>23 (17–29)</td>
<td>11 (7.6–14)</td>
<td>21 (15–27)</td>
</tr>
<tr>
<td>Total</td>
<td>36 (29–43)</td>
<td>32 (25–39)</td>
<td>32 (26–43)</td>
</tr>
</tbody>
</table>

**TB case notifications, 2017**

- Total cases notified: 27,934
- Total new and relapse: 26,294
- % tested with rapid diagnostics at time of diagnosis: 45%
- % with known HIV status: 57%
- % bacteriologically confirmed among pulmonary: 26%

**Universal health coverage and social protection**

- TB treatment coverage (notified/estimated incidence), 2017: 74% (61–91)
- TB patients facing catastrophic total costs: 0.15 (0.1–0.21)

**TB/HIV care in new and relapse TB patients, 2017**

- Patients with known HIV-status who are HIV-positive: 791
- % on antiretroviral therapy: 753
  - 791 (7%)
  - 753 (95%)

**Drug-resistant TB care, 2017**

- Estimated MDR/RR-TB cases among notified pulmonary TB cases: 960
- Estimated % of TB cases with MDR/RR-TB: 3.4% (1.7–5)
- % notified tested for rifampicin resistance: 11%
- % of pulmonary: 26% (15–36)

**Laboratory-confirmed cases**

- MDR/RR-TB: 356
- XDR-TB: 13

**Patients started on treatment ****

- MDR/RR-TB: 356
- XDR-TB: 15

**Treatment success rate and cohort size**

- Success: 62%
- Cohort: 27,294

- Previously treated cases in 2016: 17%
- 2,457

- HIV-positive TB cases registered in 2016: 68%
- 149

**TB preventive treatment, 2017**

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 16%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

**TB financing, 2018**

- National TB budget (US$ millions): 28
- Funding source: 50% domestic, 21% international, 29% unfunded

---

*Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed

---

*Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.*